DRTS
$7.47
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technolog...
Recent News
Alpha Tau price target raised to $12 from $9 at H.C. Wainwright
H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted marketing approval for Alpha DaRT for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. The approval in Japan further validates the Alpha DaRT platform and helps de-risk the clinical development in the U.S., the analyst tells investors.Claim 50% Off TipRanks Premi
New Strong Sell Stocks for January 27th
DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.
New Strong Sell Stocks for January 20th
DAR, CADL and DRTS have been added to the Zacks Rank #5 (Strong Sell) List on January 20, 2026.
Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention
As the U.S. stock market surges on news of a trade deal with the UK, investors are keenly observing how such developments might influence various sectors, including smaller-cap stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing opportunities for growth at lower price points despite being considered a somewhat outdated term. By focusing on strong financials and solid fundamentals, these under-the-radar investments can present compelling...